Investors Bet On UK/Singapore Biotech To Disrupt Personalized Skin Care

Sequential Skin, whose genetic and microbiome home test kit sells for $149, raised $1.65m in a seed round announced on 11 October. The UK/Singapore biotech will use the funds to roll out the kit in the US while extending its B2B offering to skin care, hair care and health care companies for clinical trial and product validation purposes.